Hyperuricemia has long been established as the major etiologic factor in gout. Alongside
with an inflammatory state triggered by urate crystal deposition in the joints, hyperuricemia …

There are a number of medications in the pipeline targeting hyperuricemia, mostly
uricosurics in combination with xanthine oxidase inhibitors, but some targeting both xanthine …

Several studies suggest that chronic hyperuricemia, the main precursor of gout, is involved
in the pathogenesis of different systemic disorders that affect cardiovascular and renal …

Uric acid is the final oxidation product of purine metabolism in humans. Xanthine
oxidoreductase (XOR) catalyzes oxidative hydroxylation of hypoxanthine to xanthine to uric …

Hyperuricemia is commonly associated with traditional risk factors such as dysglicemia,
dyslipidemia, central obesity and abnormal blood pressure, ie the metabolic syndrome …

Introduction: The significant proportion of gout patients not reaching serum urate levels
below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate …

Gout is the most common form of inflammatory arthritis and is a multifactorial disease
typically characterized by hyperuricemia and monosodium urate crystal deposition …

Despite being the most common type of inflammatory arthritis, gout is often poorly managed.
Except for febuxostat and pegloticase, research in new therapeutic agents for the …

The association between hyperuricemia and cardiovascular disease (CVD) has been
reported and studied in the past two decades. Xanthine oxidase (XO) induced uric acid (UA) …

There have been recent advances in the understanding of underlying mechanisms and
treatment of gout and chronic hyperuricemia, making this an important time to review the …